TNAU, Akums sign MoU to synergise pharma innovations
The Tamil Nadu Agricultural University (TNAU), Coimbatore, has signed a Memorandum of Understanding (MoU) with Akums Drugs and Pharmaceuticals to advance research and development in pharmaceutical formulations and jointly develop sustainable healthcare solutions.
The Department of Processing and Food Engineering at Agricultural Engineering College and Research Institute in the TNAU campus will explore novel applications of agri-based inputs for pharmaceutical and nutraceutical use, focusing on sustainable, plant-derived resources, while Akums will leverage its vast expertise in pharmaceutical development with TNAU's advanced agricultural research capabilities, a press release said.
The MoU provides for industrial training and internships in pharmaceutical processing and formulation techniques.
Additionally, Akums will collaborate with the Agricultural Engineering College and Research Institute (AEC&RI), Kumulur, to explore the commercialisation of novel formulations for both domestic and export markets under ICAR (Indian Council of Agricultural Research) sponsored CRP (Consortium Research Platform) on SA Project, funded by CIPHET (Central Institute of Post-Harvest Engineering and Technology), Ludhiana.
Sanjeev Jain, Managing Director of Akums Drugs and Pharmaceuticals, said the partnership holds immense potential to develop effective pharmaceutical formulations that are environmentally friendly as well. The MoU will enhance the utility of agricultural resources in healthcare, P. Rajkumar, Dean, AEC and RI, TNAU, Kumulur, added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
2 hours ago
- The Hindu
TNAU has disbursed ₹8.98 crore as grants to 85 agri startups since 2019
Tamil Nadu Agricultural University (TNAU), Coimbatore, has disbursed grants to the extent of 8.98 crore to 85 agri startups since 2019, under Rashtriya Krishi Vikas Yojana - Remunerative Approaches for Agriculture and Allied Sectors Rejuvenation (RKVY-RAFTAAR), a flagship scheme of the Union Ministry of Agriculture and Farmers' Welfare to strengthen infrastructure in Agriculture and Allied sectors. The allied sectors constitute Crop Husbandry (including Horticulture), Animal Husbandry and Fisheries, Dairy Development, Agricultural Research and Education, Forestry and Wildlife, Plantation and Agricultural Marketing, Food Storage and Warehousing, Soil and Water Conservation, Agricultural Financial Institutions, other Agricultural Programmes and Cooperation. TNAU is one among 24 R-ABIs (RKVY-RAFTAAR Agribusiness Incubators) identified by the Central Government for fostering Agripreneurship and Agri-Business ecosystem across the country, through facilitating financial aid to potential agri startups and nurturing a system of business incubation. The TNAU has been conducting two programmes under this scheme: Agripreneurship Orientation Programme (AOP) for a grant up to ₹5 lakh, and Startup Agribusiness Incubation Programme (SAIP) ) for a grant of up to ₹25 lakh. Earlier this week, R. Thamizh Vendan, Registrar and Acting Vice-Chancellor, TNAU, disbursed ₹35 lakh for 10 SAIP Cohort III Grantees as third instalment, ₹17.80 lakh for 11 AOP Cohort IV Grantees as second instalment and ₹35.40 lakh for 13 AOP Cohort V Grantees as first instalment. In total, ₹88.20 lakh were given to 34 grantees of SAIP cohort III and AOP cohort IV and V. The grant, Prof. Vendhan said, has been effective in retaining the youth in agriculture and to support agri-based startups to innovate and implement new technologies for sustainable and profitable agribusiness. The grantees have planned to utilise the grant for development of products and upscaling their startups in agri and allied ventures, E. Somasundaram, Director, Agri-Business Development, TNAU, said. RKVY-RAFTAAR, sources added, is being implemented as a Centrally-sponsored scheme in the ratio of 60:40 (Government of India and State Share respectively) except in case of north-eastern and hilly States where the sharing pattern is 90:10. For union territories, the grant is 100% as Central share.
The Hindu
30-05-2025
- The Hindu
Minister inaugurates Centrally-funded Common Incubation Centre for coconut value-addition at TNAU
The Centrally-funded Common Incubation Centre (CIC) for processing coconut products was commissioned at Tamil Nadu Agricultural University (TNAU), Coimbatore, by M. Anbarasan, State Minister for Micro, Small and Medium Enterprises (MSME), on Friday. The CIC functioning out of the Department of Food Process Engineering, Agricultural Engineering College and Research Institute, on the TNAU campus is envisaged to play a supportive role for coconut farmers, Food Processing Organisations, NGOs, and start-ups on custom-hiring basis. M. Balakrishnan, Professor and Head, Department of Food Process Engineering, TNAU, Coimbatore, explained and demonstrated various processing lines of coconut products to the Minister and senior officials. Atul Anand, Additional Chief Secretary to Government, MSME Department; L. Nirmal Raj, Industries Commissioner and Director of Industries and Commerce; and R. Thamizh Vendan, Registrar and Acting Vice- Chancellor, TNAU, Coimbatore, took part. The State Level Technical Institute (SLTI) and Micro, Small and Medium Enterprises Department, Government of Tamil Nadu, Chennai, are the State Nodal Agency (SNA) of PMFME Scheme. At another function, the TNAU signed a Memorandum of Agreement with Food and Biotech Industries. The Biotech Council for Centre of Excellence in Biotechnology (CoEB) in the university fosters research and development activities under public-private partnership mode to develop super active enzymes/biomolecules, biobased products, hormones for fruit ripening, plant growth stimulants and similar bio-inputs for the commercial benefit of farmers. Prof. Thamizh Vendan said the MoA was signed with two established companies: M/s. Pechi Foods Private Limited, Coimbatore, and M/s. Innogreen India Marketing, Madurai, for facilitating the knowledge space to develop research activities.
Fashion Value Chain
27-05-2025
- Fashion Value Chain
Akums Reports Q4 FY25 with 12.4% Revenue Growth, FY25 Adj. EBITDA Remained Strong at 12.3%
Akums Drugs and Pharmaceuticals Ltd., India's largest contract development and manufacturing organization (CDMO), has announced its consolidated financial results for the quarter and fiscal year ending March 31, 2025. The fourth quarter marked a significant rebound in performance, laying a strong foundation for continued growth and global expansion. In Q4 FY25, Akums reported revenue of Rs.1,073 crore, reflecting a robust 12.4% year-on-year (YoY) growth. The company posted a 10.4% EBITDA margin. Building on its Q4 momentum, Akums closed FY25 with consolidated total income of Rs. 4,170 crore and an adjusted EBITDA margin of 12.3%, a 7-basis point improvement from the previous year. The company continued its focus on enhancing its product mix, building a differentiated, research-driven portfolio, and expanding its global presence. One of the key developments during the fiscal year was securing an approx. €200 million contract for the manufacture and supply of pharmaceutical products to regulated European markets – a milestone that significantly expands Akums' global CDMO footprint. The commercial supplies for this will begin in 2027. To support its expanding footprint, Akums invested Rs. 272 crore in capital expenditure during FY25. which now stands at 49.6 billion units annually. This infrastructure scale-up ensures readiness for large-scale domestic CDMO operations as well as global pharma opportunities. Akums also maintained a strong R&D focus, investing Rs. 130 crore which is over 3% of revenue. With 973 DCGI approvals now, the company's product portfolio has over 4,000 commercialized formulations. This is across multiple therapeutic areas across 60+ dosage forms. Segmental Performance Overview Akums' flagship business, CDMO, contributed ~78% to the group turnover with an adjusted EBITDA of 14.1% in FY 25. The company's domestic branded formulation business segment reported ~9% growth while international branded formulation business grew by ~14%. Trade generics and API segment continue to be in operational loss this fiscal, but the company is taking firm measures to cut the losses in the coming fiscal. Strategic Focus and Future Outlook Despite making meaningful progress across key business segments, Akums reported flat year-on-year revenue, largely due to muted industry volumes and price erosion in APIs. The company, however, continued to invest in long-term growth drivers to consolidate its leadership position in India's pharmaceutical landscape and lay the foundation for global CDMO expansion. With an R&D spend, up 16% from FY24, Akums continues to deepen its innovation capabilities, develop complex formulations, and enrich its portfolio. The company's emphasis on quality-focused manufacturing, novel delivery formats, and patient-centric innovations ensures that its offerings are both globally relevant and therapeutically effective. Commenting on the results, Mr. Sanjeev Jain, Managing Director, said, ' As we look back on the year we got listed, we also look ahead with a renewed sense of purpose. Our entry into Europe is a pivotal step for the Akums' global CDMO expansion. Coupled with strategic capacity expansion and a sharp focus on differentiated offerings, we are laying the foundation for Akums to emerge as a trusted global CDMO. We remain steadfast in our commitment to creating long-term value for all stakeholders and to delivering healthcare solutions that impact lives across geographies.' Mr. Sandeep Jain, Managing Director, added, 'It gives us immense pride to close FY25 on a positive note, especially in a year marked by volatility across the pharmaceutical industry. Despite price erosion in APIs and slowing volumes, Akums remained focused on the fundamentals-operational discipline, innovation, and global ambition. Our new injectable facility is now operational, our R&D engine is stronger than ever, and our differentiated portfolio continues to resonate with partners. These are exciting times, as we accelerate our transformation into a global pharmaceutical manufacturing organization.' Here is the Summary of Profit and Loss Statement for reference P/L (Rs Cr) Q4 FY 25 Q3 FY 25 Q4 FY 24 FY 25 FY 24 Revenue 1,056 1,010 944 4,118 4,178 Other Income 18 15 10 52 34 Total income 1,073 1,025 954 4,170 4,212 COGS 639 602 569 2,433 2,550 Employee Cost 184 176 164 716 647 Other Expenses 139 111 128 508 500 Adj EBITDA 111 136 98 513 515 Adj EBITDA Margin 10.4% 13.3% 10.3% 12.3% 12.2% Depreciation 40 45 34 153 126 Finance Cost 5 5 12 35 51 Exceptional Item -8 -5 0 -17 26 Adj PAT 44 66 46 234 220 Adj PAT Margin 4.1% 6.5% 4.8% 5.6% 5.2%
